Expert Consulting in AAV Gene Therapy Solutions
Specializing in innovative AAV gene therapy, AAVion offers tailored expertise in gene delivery, expression, and comprehensive support from experimental design through final analysis, guiding you toward a successful Investigational New Drug (IND) application.
Let’s Collaborate
About
AAVion LLC is a Maryland-based consulting company specializing in Adeno-Associated Virus (AAV) biology and gene therapy. Founded and led by Dr. Prasad Konkalmatt.
We offer personalized expertise in AAV vector design, promoter and capsid engineering, and experimental designs for in-vitro and in-vivo preclinical studies to support gene therapy research and development.
The name AAVion is inspired by avion (French/Spanish for airplane) and highlights our expertise in AAV gene therapy technologies.
Who we are
Meet Dr. Prasad Konkalmatt, PhD
A Legacy of Innovation in Gene Therapy
Dr. Konkalmatt brings decades of experience in AAV biology, with a distinguished career spanning academic research at leading institutions as well as biopharmaceutical innovation in the gene therapy industry. As a pioneer in the field, Dr. Konkalmatt has contributed significantly to advancing AAV technology for therapeutic applications.
Click Here to view details of areas of expertise
Our Clients
Estuary Biotherapeutics, Inc.
Private Gene Therapy Company, Currently in Stealth
Services
AAVion LLC provides specialized consulting services in AAV gene therapy, tailored to the needs of biotechnology companies, biopharma innovators, and academic researchers. We take a customized, project-focused approach to ensure that each client’s goals are met efficiently and effectively.
Our areas of expertise include:
Preclinical Study Guidance: Strategic planning and experimental design for in vivo and in vitro studies, ensuring robust methods to achieve specific objectives.
AAV Vector Design: Providing guidance on designing AAV vectors tailored for both preclinical and clinical applications.
Promoter Engineering: Development of custom promoters to enable efficient and targeted gene expression in specific cell types.
Capsid Engineering: Development of novel AAV capsids through directed evolution, leveraging capsid library construction and advanced screening strategies to optimize targeting efficiency and specificity.
Streamlined vector design for optimized gene expression and robust experimental strategies to support IND-enabling studies and accelerate the translation of therapies from research to clinical application.
Endorsements
Hear what clients, collaborators, and peers are saying about AAVion’s expertise in AAV gene therapy
“Dr. Konkalmatt has been a long-standing, prolific, and consistent contributor to the field of AAV gene therapy. With decades of experience in effective vector design, promoter discovery, capsid engineering, and preclinical testing, he has an extensive knowledge base, inventive spirit, and solid scientific judgement to lead and advise through the challenges of gene therapy discovery, development, and translation.”
Kathy Ivey, Sr. Vice President, Research at Tenaya Therapeutics
“Prasad brings deep and practical expertise in designing novel kidney- and heart-specific AAV gene therapy tools. Estuary Biotherapeutics is proud to collaborate with domain experts like Prasad, particularly given his pioneering work in the use of promoters to target expression within specific segments of the nephron, as we advance our programs”
Wayne Sackett, Co-Founder and CEO, Estuary Biotherapeutics
“Prasad is an accomplished AAV gene therapy scientist with significant expertise in capsid and promoter engineering, in-vitro and in-vivo preclinical studies and vector design. He has a list of accomplishments that demonstrate deep understanding and creative thinking in all aspects of AAV development. During our conversations, I have learnt a great deal from Prasad and can wholeheartedly recommend him as a colleague and collaborator”
Suyash Prasad, Principal/Chief Medical Officer, @ Suyash Prasad Consulting LLC
“I recruited Dr. Prasad Konkalmatt to develop AAV vectors for targeted gene delivery to renal tubules. He collaborated closely with my team to establish retrograde ureteral delivery to renal epithelial cells and designed segment-specific expression cassettes used across multiple projects. His work demonstrating DRD2 AAV’s protective effects on renal function exemplifies his innovation and scientific rigor. Prasad’s collaborative nature and problem-solving mindset make him a valuable contributor to advancing AAV gene therapy research.”
Pedro A. Jose, MD, PhD, Professor of Medicine and Pharmacology-Physiology, The George Washington University
Begin Your Journey
Contact:
Email: pkonkalmatt@aavionsol.com
Phone: +1-434-245-1635